AAPL   392.82 (+2.38%)
MSFT   215.02 (+0.63%)
GOOGL   1,553.55 (+0.94%)
AMZN   3,271.68 (+2.24%)
NVDA   428.66 (+2.26%)
CGC   17.57 (+0.86%)
BABA   263.66 (+1.02%)
GE   6.69 (-0.15%)
TSLA   1,736.83 (+12.44%)
T   29.82 (-1.03%)
GILD   76.94 (+0.81%)
DIS   119.38 (+0.03%)
NFLX   565.54 (+3.06%)
BAC   24.09 (+0.29%)
AAPL   392.82 (+2.38%)
MSFT   215.02 (+0.63%)
GOOGL   1,553.55 (+0.94%)
AMZN   3,271.68 (+2.24%)
NVDA   428.66 (+2.26%)
CGC   17.57 (+0.86%)
BABA   263.66 (+1.02%)
GE   6.69 (-0.15%)
TSLA   1,736.83 (+12.44%)
T   29.82 (-1.03%)
GILD   76.94 (+0.81%)
DIS   119.38 (+0.03%)
NFLX   565.54 (+3.06%)
BAC   24.09 (+0.29%)
AAPL   392.82 (+2.38%)
MSFT   215.02 (+0.63%)
GOOGL   1,553.55 (+0.94%)
AMZN   3,271.68 (+2.24%)
NVDA   428.66 (+2.26%)
CGC   17.57 (+0.86%)
BABA   263.66 (+1.02%)
GE   6.69 (-0.15%)
TSLA   1,736.83 (+12.44%)
T   29.82 (-1.03%)
GILD   76.94 (+0.81%)
DIS   119.38 (+0.03%)
NFLX   565.54 (+3.06%)
BAC   24.09 (+0.29%)
AAPL   392.82 (+2.38%)
MSFT   215.02 (+0.63%)
GOOGL   1,553.55 (+0.94%)
AMZN   3,271.68 (+2.24%)
NVDA   428.66 (+2.26%)
CGC   17.57 (+0.86%)
BABA   263.66 (+1.02%)
GE   6.69 (-0.15%)
TSLA   1,736.83 (+12.44%)
T   29.82 (-1.03%)
GILD   76.94 (+0.81%)
DIS   119.38 (+0.03%)
NFLX   565.54 (+3.06%)
BAC   24.09 (+0.29%)
Log in

CVE:ATEAntibe Therapeutics Stock Price, Forecast & News

C$0.39
+0.01 (+1.30 %)
(As of 07/13/2020 09:57 AM ET)
Add
Compare
Today's Range
C$0.39
Now: C$0.39
C$0.40
50-Day Range
C$0.38
MA: C$0.52
C$0.77
52-Week Range
C$0.28
Now: C$0.39
C$0.89
Volume104,393 shs
Average Volume1.75 million shs
Market CapitalizationC$137.73 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of cardiovascular disease and cancer chemoprevention. In addition, it offers various tissue regenerating products, such as bone grafting and dental membrane solutions for the dental and orthopedic markets; and surgical instruments for dental surgery, plastic surgery, general surgery and specialties, and veterinary applications. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.73 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-905-5705103

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$10.07 million
Cash FlowC$0.02 per share
Book ValueC$0.03 per share

Profitability

Miscellaneous

Employees37
Market CapC$137.73 million
Next Earnings Date8/25/2020 (Estimated)
OptionableNot Optionable

Receive ATE News and Ratings via Email

Sign-up to receive the latest news and ratings for ATE and its competitors with MarketBeat's FREE daily newsletter.

Antibe Therapeutics (CVE:ATE) Frequently Asked Questions

How has Antibe Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Antibe Therapeutics' stock was trading at C$0.56 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ATE shares have decreased by 30.4% and is now trading at C$0.39. View which stocks have been most impacted by Coronavirus.

When is Antibe Therapeutics' next earnings date?

Antibe Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 25th 2020. View our earnings forecast for Antibe Therapeutics.

Has Antibe Therapeutics been receiving favorable news coverage?

News coverage about ATE stock has trended very negative on Monday, InfoTrie reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Antibe Therapeutics earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Antibe Therapeutics.

Who are some of Antibe Therapeutics' key competitors?

What other stocks do shareholders of Antibe Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antibe Therapeutics investors own include Resverlogix (RVX), Terra Tech (TRTC), Green Bancorp (GNBC), Cartier Iron (CFE), Maxar Technologies (MAXR), Nemaska Lithium (NMX), Royal Bank of Canada (RY), Scorpio Gold (SGN), Suncor Energy (SU) and Bank of America (BAC).

Who are Antibe Therapeutics' key executives?

Antibe Therapeutics' management team includes the following people:
  • Mr. Daniel Marcel Legault, Pres, CEO, Sec. & Director (Age 61)
  • Dr. John Lawrence Wallace, Founder, Chief Scientific Officer & Director (Age 62)
  • Mr. Alain Wilson MBA, Chief Financial Officer
  • Mr. Scott Curtis M.Eng, CFA, VP of Corp. Devel.
  • Dr. David James Vaughan Ph.D., Chief Devel. Officer (Age 69)

What is Antibe Therapeutics' stock symbol?

Antibe Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ATE."

How do I buy shares of Antibe Therapeutics?

Shares of ATE and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Antibe Therapeutics' stock price today?

One share of ATE stock can currently be purchased for approximately C$0.39.

How big of a company is Antibe Therapeutics?

Antibe Therapeutics has a market capitalization of C$137.73 million and generates C$10.07 million in revenue each year. Antibe Therapeutics employs 37 workers across the globe.

What is Antibe Therapeutics' official website?

The official website for Antibe Therapeutics is www.antibethera.com.

How can I contact Antibe Therapeutics?

Antibe Therapeutics' mailing address is 15 Prince Arthur Ave, TORONTO, ON M5R 1B2, Canada. The company can be reached via phone at +1-905-5705103.

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.